CD8A and neoplasm: Phenotypic characterization of TILs across the different treatment groups showed a significant and preferential ~20-fold expansion of CD8+ over CD4+ T cells in tumours from mice treated with muPD1-IL2v, compared with the control and other treatment groups (Fig. 3e).